XJZY(SZ:002332)2022-04-20 16:00Financial Performance - The company reported a total revenue of 1.2 billion CNY for the year 2021, representing a year-on-year growth of 15%[5]. - The net profit attributable to shareholders was 250 million CNY, an increase of 20% compared to the previous year[5]. - The company's operating revenue for 2021 was ¥4,337,150,964.75, representing a 7.92% increase from ¥4,018,872,772.40 in 2020[28]. - Net profit attributable to shareholders for 2021 was ¥615,942,771.05, a 22.09% increase compared to ¥504,509,427.41 in 2020[28]. - The net profit after deducting non-recurring gains and losses was ¥581,194,088.37, reflecting a 26.46% increase from ¥459,591,327.12 in 2020[28]. - The company achieved operating revenue of CNY 4.34 billion, a year-on-year increase of 7.92%[59]. - Net profit attributable to shareholders reached CNY 615.94 million, up 22.09% year-on-year, with earnings per share of CNY 0.62, reflecting a 12.73% increase[51]. - The company reported a total revenue of 14,691,834,000, with a net profit of 1,520,640,000 for the fiscal year[186]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2021, representing a year-over-year growth of 15%[199]. - The net profit for the year was 300 million RMB, an increase of 20% compared to the previous year[199]. User Engagement and Market Expansion - The company highlighted a significant increase in user data, with a 30% rise in active users of its pharmaceutical products[5]. - User data showed a 25% increase in active users, reaching 2 million by the end of 2021[199]. - Future outlook includes a projected revenue growth of 10% for 2022, driven by new product launches and market expansion strategies[5]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2023[199]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by 2023[158]. Research and Development - The company is investing 200 million CNY in R&D for new drug development in the next fiscal year[5]. - The company has received five national invention patents during the reporting period, indicating strong R&D capabilities[54]. - The company is developing multiple new products in gynecology and anesthesia, aiming to expand its product lines[88]. - The company is committed to accelerating product research and development, focusing on key products such as progesterone gel and mometasone nasal spray, while also pursuing new formulation breakthroughs[140]. - The company is investing 100 million RMB in R&D for new technologies in the pharmaceutical sector[199]. Operational Efficiency and Cost Control - The company has optimized its production system and applied new technologies to improve operational efficiency and market responsiveness[47]. - The company has optimized its internal management and cost control, resulting in significant operational efficiency improvements[51]. - The company is implementing lean production management to improve operational efficiency and transition from a "cost center" to a "profit center" approach[140]. - The company aims to reduce operational costs by 5% through efficiency improvements in the supply chain[199]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost control measures[158]. Strategic Initiatives and Acquisitions - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[5]. - A strategic acquisition of a smaller biotech firm was completed, enhancing the company's R&D capabilities and expected to add 50 million RMB in annual revenue[158]. - The company plans to enhance its internationalization of chemical raw materials, using Newchem as a benchmark for global steroid hormone industry chain integration[135]. - The company aims to leverage its existing market presence to explore potential mergers and acquisitions in the pharmaceutical sector[187]. Risk Management and Compliance - The management identified risks including regulatory changes and rising operational costs, which could impact future performance[5]. - The company aims to improve its quality control processes to mitigate risks associated with product recalls and compliance issues[5]. - New regulations in drug management and quality control require the company to improve its operational quality and ensure compliance throughout the drug lifecycle[145]. - The company recognizes the risk of talent shortages as it expands and integrates acquisitions, emphasizing the need for skilled professionals[147]. Corporate Governance and Investor Relations - The company actively respects and protects the rights of stakeholders, promoting balanced interests among shareholders, employees, and society[170]. - The company has established a robust information disclosure system, ensuring timely and accurate communication with investors[171]. - The company has plans for market expansion and new product development, focusing on innovative pharmaceutical solutions[187]. - The company is committed to enhancing corporate governance and investor relations, ensuring timely and accurate information disclosure to protect investor rights[141].